Breast cancer: high androgen receptor in Korean cohort tied to better survival

  • Hwang KT & al.
  • J Clin Med
  • 10 Apr 2020

  • curated by Miriam Davis, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • High vs low expression of androgen receptor (AR) in nonmetastatic breast cancer is an independent prognostic marker of superior survival.

Why this matters

  • Findings suggest that AR may be clinically useful as a prognostic marker.

Study design

  • Prospective cohort study comparing high vs low AR expression, using immunohistochemistry on tissue microarrays from 395 patients with breast cancer (excluding stage IV) at a Korean center (1999-2012).
  • Funding: Korea Breast Cancer Foundation; others.

Key results

  • Mean follow-up: OS, 120.8±51.0 months; DFS, 87.5±50.5 months.
  • High vs low AR expression was associated with better OS (P=.047), DFS (P=.004), and systemic recurrence-free survival (P=.027).
  • In multivariate analysis, high AR was an independent prognostic factor for superior OS (HR, 0.586; P=.015) and DFS (HR, 0.430; P<.001>
  • Features of the subgroup showing high AR as an independent prognostic factor for DFS were positive hormone receptor and negative human epidermal growth factor receptor 2 (P=.026).

Limitations

  • Single center.
  • Observational.